The Experts below are selected from a list of 72 Experts worldwide ranked by ideXlab platform
Soon Ho Um - One of the best experts on this subject based on the ideXlab platform.
-
a comparative study of high dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable advanced hepatocellular carcinoma
The Korean Journal of Hepatology, 2010Co-Authors: Jun Yong Park, Jong Young Choi, Seung Kew Yoon, Byoung Kuk Jang, Jae Seok Hwang, Soon Ho UmAbstract:Background/Aims: Transarterial chemoembolization (TACE) has long been used as a palliative therapy for unresectable hepatocellular carcinoma (HCC). High-dose hepatic arterial infusion chemotherapy (HAIC) has showed favorable outcomes in patients with intractable, advanced HCC. The aim of this study was to compare the effectiveness and safety of high-dose HAIC and conventional TACE using doxorubicin for advanced HCC. Methods: The high-dose HAIC group comprised 36 patients who were enrolled prospectively from six institutions. The enrollment criteria were good liver function, main Portal vein invasion (including vascular shunt), infiltrative type, bilobar involvement, and/or refractory to prior conventional treatment (TACE, radiofrequency ablation, or percutaneous ethanol injection), and documented progressive disease. Patients received 5-fluorouracil (500 mg/m 2 on days 1~3) and cisplatin (60 mg/m 2 on day 2 every 4 weeks) via an Implantable Port System. In the TACE group, 31 patients with characteristics similar to those in the high-dose HAIC group were recruited retrospectively from a single center. Patients underwent a transarterial infusion of doxorubicin every 4~8 weeks. Results: Overall, 6 patients (8.9%) achieved a partial response and 20 patients (29.8%) had stable disease. The objective response rate (complete response+partial response) was significantly better in the high-dose HAIC group than in the TACE group (16.7% vs. 0%, P=0.030). Overall survival was longer in the high-dose HAIC group than in the TACE group (median survival, 193 vs. 119 days; P=0.026). There were no serious adverse effects in the high-dose HAIC group, while hepatic complications occurred more often in the TACE group. Conclusions: High-dose HAIC appears to improve the tumor response and survival outcome compared to conventional TACE using doxorubicin in patients with intractable, advanced HCC. (Korean J Hepatol 2010;16:355-361)
-
a randomized comparative study of high dose and low dose hepatic arterial infusion chemotherapy for intractable advanced hepatocellular carcinoma
Cancer Chemotherapy and Pharmacology, 2010Co-Authors: Jun Yong Park, Ho Jong Chun, Byung Gil Choi, Hyeon U Im, Jong Young Choi, Seung Kew Yoon, Jae Youn Cheong, Byoung Kuk Jang, Jae Seok Hwang, Soon Ho UmAbstract:Purpose Hepatic arterial infusion chemotherapy (HAIC) has been rePorted to be eVective in patients with advanced hepatocellular carcinoma (HCC). Methods In this multicenter, prospective, open-labeled, clinical trial, we randomly assigned 68 patients with advanced HCC to receive either low-dose [n = 32, 5-Xuorouracil (FU), 170 mg/m 2 and cisplatin, 7 mg/m 2 on days 1– 5] or high-dose HAIC (n = 36, 5-FU, 500 mg/m 2 on days 1–3 and cisplatin, 60 mg/m 2 on day 2) every 4 weeks via an Implantable Port System. Results A total of 207 cycles of HAIC was given to the 68 patients. Overall, 6 patients (8.8%) achieved a partial response and 21 patients (30.9%) had stable disease. The objective response rate (CR + PR) was signiWcantly improved in the high-dose group compared to the low-dose group (16.7% vs. 0%, P = 0.024). The median time to disease progression and overall survival were slightly prolonged in the high-dose group compared to the low-dose group (median survival, 193 vs. 153 days; P = 0.108; median time to disease progression, 145 vs. 90 days; P = 0.095). Multivariate analysis showed that tumor response to treatment [P = 0.007, RR 2.27 (95% CI, 1.248– 4.132)] was the only factor associated with overall survival. All adverse events were tolerable and successfully managed in both treatment groups. Conclusions Both HAIC regimens are safe and eVective in patients with advanced HCC. High-dose HAIC achieves a better tumor response compared to low-dose HAIC.
Jun Yong Park - One of the best experts on this subject based on the ideXlab platform.
-
a comparative study of high dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable advanced hepatocellular carcinoma
The Korean Journal of Hepatology, 2010Co-Authors: Jun Yong Park, Jong Young Choi, Seung Kew Yoon, Byoung Kuk Jang, Jae Seok Hwang, Soon Ho UmAbstract:Background/Aims: Transarterial chemoembolization (TACE) has long been used as a palliative therapy for unresectable hepatocellular carcinoma (HCC). High-dose hepatic arterial infusion chemotherapy (HAIC) has showed favorable outcomes in patients with intractable, advanced HCC. The aim of this study was to compare the effectiveness and safety of high-dose HAIC and conventional TACE using doxorubicin for advanced HCC. Methods: The high-dose HAIC group comprised 36 patients who were enrolled prospectively from six institutions. The enrollment criteria were good liver function, main Portal vein invasion (including vascular shunt), infiltrative type, bilobar involvement, and/or refractory to prior conventional treatment (TACE, radiofrequency ablation, or percutaneous ethanol injection), and documented progressive disease. Patients received 5-fluorouracil (500 mg/m 2 on days 1~3) and cisplatin (60 mg/m 2 on day 2 every 4 weeks) via an Implantable Port System. In the TACE group, 31 patients with characteristics similar to those in the high-dose HAIC group were recruited retrospectively from a single center. Patients underwent a transarterial infusion of doxorubicin every 4~8 weeks. Results: Overall, 6 patients (8.9%) achieved a partial response and 20 patients (29.8%) had stable disease. The objective response rate (complete response+partial response) was significantly better in the high-dose HAIC group than in the TACE group (16.7% vs. 0%, P=0.030). Overall survival was longer in the high-dose HAIC group than in the TACE group (median survival, 193 vs. 119 days; P=0.026). There were no serious adverse effects in the high-dose HAIC group, while hepatic complications occurred more often in the TACE group. Conclusions: High-dose HAIC appears to improve the tumor response and survival outcome compared to conventional TACE using doxorubicin in patients with intractable, advanced HCC. (Korean J Hepatol 2010;16:355-361)
-
a randomized comparative study of high dose and low dose hepatic arterial infusion chemotherapy for intractable advanced hepatocellular carcinoma
Cancer Chemotherapy and Pharmacology, 2010Co-Authors: Jun Yong Park, Ho Jong Chun, Byung Gil Choi, Hyeon U Im, Jong Young Choi, Seung Kew Yoon, Jae Youn Cheong, Byoung Kuk Jang, Jae Seok Hwang, Soon Ho UmAbstract:Purpose Hepatic arterial infusion chemotherapy (HAIC) has been rePorted to be eVective in patients with advanced hepatocellular carcinoma (HCC). Methods In this multicenter, prospective, open-labeled, clinical trial, we randomly assigned 68 patients with advanced HCC to receive either low-dose [n = 32, 5-Xuorouracil (FU), 170 mg/m 2 and cisplatin, 7 mg/m 2 on days 1– 5] or high-dose HAIC (n = 36, 5-FU, 500 mg/m 2 on days 1–3 and cisplatin, 60 mg/m 2 on day 2) every 4 weeks via an Implantable Port System. Results A total of 207 cycles of HAIC was given to the 68 patients. Overall, 6 patients (8.8%) achieved a partial response and 21 patients (30.9%) had stable disease. The objective response rate (CR + PR) was signiWcantly improved in the high-dose group compared to the low-dose group (16.7% vs. 0%, P = 0.024). The median time to disease progression and overall survival were slightly prolonged in the high-dose group compared to the low-dose group (median survival, 193 vs. 153 days; P = 0.108; median time to disease progression, 145 vs. 90 days; P = 0.095). Multivariate analysis showed that tumor response to treatment [P = 0.007, RR 2.27 (95% CI, 1.248– 4.132)] was the only factor associated with overall survival. All adverse events were tolerable and successfully managed in both treatment groups. Conclusions Both HAIC regimens are safe and eVective in patients with advanced HCC. High-dose HAIC achieves a better tumor response compared to low-dose HAIC.
-
repetitive short course hepatic arterial infusion chemotherapy with high dose 5 fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma
Cancer, 2007Co-Authors: Jun Yong Park, Young Joon Yoon, Chae Yoon Chon, Young Myoung MoonAbstract:BACKGROUND. Hepatic arterial infusion chemotherapy (HAIC) has often been selected as a therapeutic option for patients with advanced hepatocellular carcinoma (HCC). The objective of the current study was to evaluate the efficacy and safety of repetitive HAIC with high-dose 5-fluorouracil (5-FU) and cisplatin given for 3 days in patients with advanced HCC. METHODS. Between January 2001 and December 2004, a total of 41 patients with unresectable advanced HCC were enrolled. The patients underwent HAIC via the Implantable Port System with 5-FU (at a dose of 500 mg/m2 on Days 1–3) and cisplatin (at a dose of 60 mg/m2 on Day 2) every 4 weeks. Tumor response was assessed at the end of every 3 cycles. RESULTS. The median age of the patients was 53 years and 34 patients (82.9%) had evidence of Portal vein thrombosis. In total, 230 cycles of HAIC were administered to the 41 patients, with a median of 6 cycles given (range, 1–14 cycles). Nine patients (22.0%) achieved a partial response and 14 patients (34.1%) had stable disease. The median time to disease progression and overall survival were 7.0 months and 12.0 months, respectively. The overall survival was found to be significantly longer in the successful disease control group (patients with a complete response, partial response, and stable disease) than in the disease progression group (median of 14.0 months vs 6.0 months; P < .001). Adverse reactions were tolerable and successfully managed with conservative treatment. CONCLUSIONS. HAIC with high-dose 5-FU and cisplatin given for 3 days achieved effective and safe results in patients with advanced HCC. Therefore, repetitive short-course HAIC with high-dose 5-FU and cisplatin may be useful as an alternative therapeutic option for patients with advanced HCC. Cancer 2007. © 2007 American Cancer Society.
Hiroshi Seki - One of the best experts on this subject based on the ideXlab platform.
-
using slow infusion mr arteriography and an Implantable Port System to assess drug distribution at hepatic arterial infusion chemotherapy
American Journal of Roentgenology, 2003Co-Authors: Hiroshi Seki, Toshirou Ozaki, Satoshi Takaki, Hiroyuki Ooi, Junichi Oda, Makoto ShiinaAbstract:OBJECTIVE. The purpose of this study was to assess perfusion patterns seen on slow-infusion MR arteriography using the hepatic arterial infusion System compared with those seen on CT arteriography.SUBJECTS AND METHODS. In 37 patients with liver metastases who had Implantable Port Systems for hepatic arterial infusion chemotherapy, slow-infusion MR arteriography using an infusion rate of 10 mL/hr through an Implantable Port and CT arteriography using an injection rate of 0.7 mL/sec were performed. In 15 of 37 patients, we evaluated enhancement patterns of tumors of the liver and visceral organs using slow-infusion MR arteriography. In all 37 patients, we compared slow-infusion MR arteriography with CT arteriography concerning intra- and extrahepatic perfusion patterns.RESULTS. On slow-infusion MR arteriography performed 10-20 min after initiation of infusion, tumors of the liver revealed significant enhancement with only a slight effect of Systemic enhancement. In seven (19%) of 37 patients, intrahepatic d...
-
mr arteriography using an Implantable Port System a new method in assessing perfusion abnormalities during hepatic arterial infusion chemotherapy
Journal of Computer Assisted Tomography, 2000Co-Authors: Hiroshi Seki, Motomasa Kimura, Norihiko Yoshimura, Toshirou Ozaki, Satoshi Takaki, Tooru Takano, Kunio SakaiAbstract:We present a case in which MR arteriography (MRA) with an indwelling catheter was used in a perfusion study of intrahepatic arterial chemotherapy for liver metastases. After embolization of collateral vessels using platinum coils, CT imaging was disturbed by strong artifact. However, platinum coils produced no MR artifact. In addition, MRA had greater advantages in depicting perfusion defects than perfusion scintigraphy. We consider MRA useful in assessing perfusion abnormalities during intrahepatic arterial chemotherapy.
-
hepatic arterial infusion chemotherapy using percutaneous catheter placement with an Implantable Port assessment of factors affecting patency of the hepatic artery
Clinical Radiology, 1999Co-Authors: Hiroshi Seki, S Yamamoto, Motomasa Kimura, Norihiko Yoshimura, Toshirou Ozaki, Kunio SakaiAbstract:Abstract OBJECTIVE: To assess the factors affecting patency of the hepatic artery during hepatic arterial infusion chemotherapy (HAIC) with an Implantable Port System inserted percutaneously. PATIENTS AND METHODS: Ninety patients with malignant hepatic tumours were given HAIC using percutaneous catheter placement. An end-hole catheter was inserted into the hepatic artery (conventional method) in 41 patients. An end-closed and side-hole catheter was used in 49 patients, in which the catheter tip was fixed in the gastroduodenal artery and the side hole was placed in the common hepatic artery (fixed catheter-tip method). The patency of the hepatic artery was evaluated with computed tomography (CT) arteriography using the Implantable Port System and angiography. Then, the factors affecting hepatic arterial patency were analysed. RESULTS: Hepatic arterial occlusion was observed in 15 patients (17%). The overall patency of the hepatic artery was 86.9%, 78.4% and 51.5% at 6 months, 1 year and 2 years, respectively. The patency rate of the hepatic artery was significantly higher in patients with catheter placement using fixed catheter-tip method than those using conventional method ( P = 0.01), and in patients without transcatheter arterial chemoembolization (TACE) prior to catheter placement than those with prior TACE ( P = 0.01). When the variables affecting patency of the hepatic artery were studied together by multivariate analyses, the imPortant factors were the method of catheter placement and the presence or absence of prior TACE. CONCLUSION: We consider that it is imPortant for long-term patency of the hepatic artery during HAIC to use fixed catheter-tip method for percutaneous catheter placement instead of conventional method, and to select patients without prior TACE.
-
hepatic perfusion abnormalities during treatment with hepatic arterial infusion chemotherapy value of ct arteriography using an Implantable Port System
Journal of Computer Assisted Tomography, 1996Co-Authors: Hiroshi Seki, Motomasa Kimura, Takeshi Kamura, Tsutomu Miura, Norihiko Yoshimura, Kunio SakaiAbstract:Purpose : The purpose of this study was to evaluate CT arteriography (CTA) using an Implantable Port System in the detection of perfusion abnormalities occurring during hepatic arterial infusion chemotherapy (HAIC). Method : In 51 patients with unresectable primary and metastatic liver tumors, who had implanted Port Systems for HAIC, CTA examinations through the infusion pump were performed. When perfusion abnormalities were found, selective angiography and/or digital subtraction angiography using the Implantable Port System were performed to determine the etiology. Results : Forty-nine perfusion abnormalities were detected in 32 patients. Intrahepatic hypoperfusion was found in 24 cases. Of 11 patients in whom correction of the hypoperfusion was attempted, it was successful in 10. Of 13 patients in whom correction was not attempted, 6 patients showed progressive disease in nonperfused areas. Intrahepatic hyperperfusion was found in 14 cases, which showed no subsequent complication. Extrahepatic perfusion was found in 11 cases. Conclusion : We consider CTA to be useful in detecting perfusion abnormalities that may compromise HAIC.
Jong Young Choi - One of the best experts on this subject based on the ideXlab platform.
-
a comparative study of high dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable advanced hepatocellular carcinoma
The Korean Journal of Hepatology, 2010Co-Authors: Jun Yong Park, Jong Young Choi, Seung Kew Yoon, Byoung Kuk Jang, Jae Seok Hwang, Soon Ho UmAbstract:Background/Aims: Transarterial chemoembolization (TACE) has long been used as a palliative therapy for unresectable hepatocellular carcinoma (HCC). High-dose hepatic arterial infusion chemotherapy (HAIC) has showed favorable outcomes in patients with intractable, advanced HCC. The aim of this study was to compare the effectiveness and safety of high-dose HAIC and conventional TACE using doxorubicin for advanced HCC. Methods: The high-dose HAIC group comprised 36 patients who were enrolled prospectively from six institutions. The enrollment criteria were good liver function, main Portal vein invasion (including vascular shunt), infiltrative type, bilobar involvement, and/or refractory to prior conventional treatment (TACE, radiofrequency ablation, or percutaneous ethanol injection), and documented progressive disease. Patients received 5-fluorouracil (500 mg/m 2 on days 1~3) and cisplatin (60 mg/m 2 on day 2 every 4 weeks) via an Implantable Port System. In the TACE group, 31 patients with characteristics similar to those in the high-dose HAIC group were recruited retrospectively from a single center. Patients underwent a transarterial infusion of doxorubicin every 4~8 weeks. Results: Overall, 6 patients (8.9%) achieved a partial response and 20 patients (29.8%) had stable disease. The objective response rate (complete response+partial response) was significantly better in the high-dose HAIC group than in the TACE group (16.7% vs. 0%, P=0.030). Overall survival was longer in the high-dose HAIC group than in the TACE group (median survival, 193 vs. 119 days; P=0.026). There were no serious adverse effects in the high-dose HAIC group, while hepatic complications occurred more often in the TACE group. Conclusions: High-dose HAIC appears to improve the tumor response and survival outcome compared to conventional TACE using doxorubicin in patients with intractable, advanced HCC. (Korean J Hepatol 2010;16:355-361)
-
a randomized comparative study of high dose and low dose hepatic arterial infusion chemotherapy for intractable advanced hepatocellular carcinoma
Cancer Chemotherapy and Pharmacology, 2010Co-Authors: Jun Yong Park, Ho Jong Chun, Byung Gil Choi, Hyeon U Im, Jong Young Choi, Seung Kew Yoon, Jae Youn Cheong, Byoung Kuk Jang, Jae Seok Hwang, Soon Ho UmAbstract:Purpose Hepatic arterial infusion chemotherapy (HAIC) has been rePorted to be eVective in patients with advanced hepatocellular carcinoma (HCC). Methods In this multicenter, prospective, open-labeled, clinical trial, we randomly assigned 68 patients with advanced HCC to receive either low-dose [n = 32, 5-Xuorouracil (FU), 170 mg/m 2 and cisplatin, 7 mg/m 2 on days 1– 5] or high-dose HAIC (n = 36, 5-FU, 500 mg/m 2 on days 1–3 and cisplatin, 60 mg/m 2 on day 2) every 4 weeks via an Implantable Port System. Results A total of 207 cycles of HAIC was given to the 68 patients. Overall, 6 patients (8.8%) achieved a partial response and 21 patients (30.9%) had stable disease. The objective response rate (CR + PR) was signiWcantly improved in the high-dose group compared to the low-dose group (16.7% vs. 0%, P = 0.024). The median time to disease progression and overall survival were slightly prolonged in the high-dose group compared to the low-dose group (median survival, 193 vs. 153 days; P = 0.108; median time to disease progression, 145 vs. 90 days; P = 0.095). Multivariate analysis showed that tumor response to treatment [P = 0.007, RR 2.27 (95% CI, 1.248– 4.132)] was the only factor associated with overall survival. All adverse events were tolerable and successfully managed in both treatment groups. Conclusions Both HAIC regimens are safe and eVective in patients with advanced HCC. High-dose HAIC achieves a better tumor response compared to low-dose HAIC.
Seung Kew Yoon - One of the best experts on this subject based on the ideXlab platform.
-
a comparative study of high dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable advanced hepatocellular carcinoma
The Korean Journal of Hepatology, 2010Co-Authors: Jun Yong Park, Jong Young Choi, Seung Kew Yoon, Byoung Kuk Jang, Jae Seok Hwang, Soon Ho UmAbstract:Background/Aims: Transarterial chemoembolization (TACE) has long been used as a palliative therapy for unresectable hepatocellular carcinoma (HCC). High-dose hepatic arterial infusion chemotherapy (HAIC) has showed favorable outcomes in patients with intractable, advanced HCC. The aim of this study was to compare the effectiveness and safety of high-dose HAIC and conventional TACE using doxorubicin for advanced HCC. Methods: The high-dose HAIC group comprised 36 patients who were enrolled prospectively from six institutions. The enrollment criteria were good liver function, main Portal vein invasion (including vascular shunt), infiltrative type, bilobar involvement, and/or refractory to prior conventional treatment (TACE, radiofrequency ablation, or percutaneous ethanol injection), and documented progressive disease. Patients received 5-fluorouracil (500 mg/m 2 on days 1~3) and cisplatin (60 mg/m 2 on day 2 every 4 weeks) via an Implantable Port System. In the TACE group, 31 patients with characteristics similar to those in the high-dose HAIC group were recruited retrospectively from a single center. Patients underwent a transarterial infusion of doxorubicin every 4~8 weeks. Results: Overall, 6 patients (8.9%) achieved a partial response and 20 patients (29.8%) had stable disease. The objective response rate (complete response+partial response) was significantly better in the high-dose HAIC group than in the TACE group (16.7% vs. 0%, P=0.030). Overall survival was longer in the high-dose HAIC group than in the TACE group (median survival, 193 vs. 119 days; P=0.026). There were no serious adverse effects in the high-dose HAIC group, while hepatic complications occurred more often in the TACE group. Conclusions: High-dose HAIC appears to improve the tumor response and survival outcome compared to conventional TACE using doxorubicin in patients with intractable, advanced HCC. (Korean J Hepatol 2010;16:355-361)
-
a randomized comparative study of high dose and low dose hepatic arterial infusion chemotherapy for intractable advanced hepatocellular carcinoma
Cancer Chemotherapy and Pharmacology, 2010Co-Authors: Jun Yong Park, Ho Jong Chun, Byung Gil Choi, Hyeon U Im, Jong Young Choi, Seung Kew Yoon, Jae Youn Cheong, Byoung Kuk Jang, Jae Seok Hwang, Soon Ho UmAbstract:Purpose Hepatic arterial infusion chemotherapy (HAIC) has been rePorted to be eVective in patients with advanced hepatocellular carcinoma (HCC). Methods In this multicenter, prospective, open-labeled, clinical trial, we randomly assigned 68 patients with advanced HCC to receive either low-dose [n = 32, 5-Xuorouracil (FU), 170 mg/m 2 and cisplatin, 7 mg/m 2 on days 1– 5] or high-dose HAIC (n = 36, 5-FU, 500 mg/m 2 on days 1–3 and cisplatin, 60 mg/m 2 on day 2) every 4 weeks via an Implantable Port System. Results A total of 207 cycles of HAIC was given to the 68 patients. Overall, 6 patients (8.8%) achieved a partial response and 21 patients (30.9%) had stable disease. The objective response rate (CR + PR) was signiWcantly improved in the high-dose group compared to the low-dose group (16.7% vs. 0%, P = 0.024). The median time to disease progression and overall survival were slightly prolonged in the high-dose group compared to the low-dose group (median survival, 193 vs. 153 days; P = 0.108; median time to disease progression, 145 vs. 90 days; P = 0.095). Multivariate analysis showed that tumor response to treatment [P = 0.007, RR 2.27 (95% CI, 1.248– 4.132)] was the only factor associated with overall survival. All adverse events were tolerable and successfully managed in both treatment groups. Conclusions Both HAIC regimens are safe and eVective in patients with advanced HCC. High-dose HAIC achieves a better tumor response compared to low-dose HAIC.